A genetically modified bacterium that outcompetes bacteria causing tooth decay
A proposed oral treatment uses a genetically modified strain of Streptococcus mutans designed to outcompete cavity-causing bacteria by producing a bacteriocin and metabolizing sugar without generating tooth-dissolving acid. Commenters weigh its promise as a one-time, potentially heritable fix for tooth decay against serious concerns about safety, weak evidence, regulatory workarounds, and the broader risks of releasing a persistent engineered microbe into the human microbiome. The exchange also touches on alternatives like conventional oral probiotics, sugar alcohols such as xylitol, and the role of genetics and diet in dental health.
Regulation and FDA behavior
- Several commenters see the historical FDA requirements (e.g., denture‑wearing young adults) as effectively impossible and potentially influenced by incumbents or litigation risk.
- Others argue the story is exaggerated or misrepresented; they cite a newspaper piece describing a smaller denture‑only safety trial as more reasonable.
- There is debate over whether the original company sought approval as a drug vs. probiotic, with differing regulatory burdens.
- Some suggest trying approval in other jurisdictions (EU, Japan, Asia); the absence of such attempts is used by skeptics as a red flag.
Plausibility of the engineered S. mutans strain
- Supporters point to the described modifications: producing mutacin-1140, avoiding lactic acid, and blocking gene transfer, plus reported year‑long colonization after one treatment.
- A microbiome-focused commenter challenges core claims:
- S. mutans normally needs low pH and lactic acid production to colonize; removing acid should make colonization hard.
- Oral microbiomes are highly stable and hard to replace with a single inoculation.
- Multiple species, not just S. mutans, cause cavities.
Evidence, effectiveness, and “scam” concerns
- Some think the narrative around “impossible FDA demands” and launching via a lightly regulated jurisdiction resembles classic startup/health‑product scams.
- Others counter that the technical write‑up, long development history, and some independent reporting make outright fraud unlikely but agree that evidence is still thin.
- People emphasize the need for long‑term, well‑designed trials tracking actual cavity rates, not just colonization.
Safety, ethics, and ecological risks
- Many are uneasy about permanently colonizing humans with a genetically modified organism that can spread via kissing.
- Comparisons are made to invasive species and biological control gone wrong; others note precedents like fecal transplants and engineered probiotics.
- Concerns include continuous local antibiotic exposure, resistance, unknown systemic roles of lactic acid, and lack of clear “kill switch.”
Alternative approaches and existing products
- Commenters mention current oral probiotics (e.g., ProBiora, BLIS M18, other brands), with mixed or negative user anecdotes.
- Xylitol and erythritol rinses are discussed, with links to studies suggesting they inhibit S. mutans biofilms.
- Basic hygiene, sugar reduction, and interdental cleaning are repeatedly raised as proven, if imperfect, strategies.
Personal anecdotes and variability
- Many report either near‑cavity‑free lives with modest care or frequent cavities despite good hygiene, suggesting strong genetic/biome factors.
- Some notice changes after partners, supporting the idea of transmissible oral microbiomes, though details remain unclear.